Parallel RNA interference screens identify EGFR activation as an escape mechanism in FGFR3-mutant cancer.
about
Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical applicationA place for precision medicine in bladder cancer: targeting the FGFRs.Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.Phase Ib study of dovitinib in combination with gemcitabine plus cisplatin or gemcitabine plus carboplatin in patients with advanced solid tumorsBiomarkers for bladder cancer management: present and future.Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors.Multiple receptor tyrosine kinase activation attenuates therapeutic efficacy of the fibroblast growth factor receptor 2 inhibitor AZD4547 in FGFR2 amplified gastric cancer.Novel molecular targets for urothelial carcinomaSummary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder CancerFGFR3-TACC3 fusion proteins act as naturally occurring drivers of tumor resistance by functionally substituting for EGFR/ERK signaling.High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical TrialAcquired resistance to LY2874455 in FGFR2-amplified gastric cancer through an emergence of novel FGFR2-ACSL5 fusion.Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer.Approaches targeting the FGF-FGFR system: a review of the recent patent literature and associated advanced therapeutic agents.Targeted therapies in bladder cancer: an overview of in vivo research.Akt Activation Mediates Acquired Resistance to Fibroblast Growth Factor Receptor Inhibitor BGJ398.Combine and conquer: challenges for targeted therapy combinations in early phase trials.Systemic therapy for metastatic bladder cancer in 2016 and beyond.Epithelial-mesenchymal transition confers resistance to selective FGFR inhibitors in SNU-16 gastric cancer cellsFGFR1 activation is an escape mechanism in human lung cancer cells resistant to afatinib, a pan-EGFR family kinase inhibitor.Ligand-associated ERBB2/3 activation confers acquired resistance to FGFR inhibition in FGFR3-dependent cancer cells.FGFR-TACC gene fusions in human glioma.Advances and challenges in targeting FGFR signalling in cancer.FGFR3-TACC3 cancer gene fusions cause mitotic defects by removal of endogenous TACC3 from the mitotic spindlePrecision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy.Resistance mediated by alternative receptor tyrosine kinases in FGFR1-amplified lung cancer.An FGFR3/MYC positive feedback loop provides new opportunities for targeted therapies in bladder cancers.RAS-MAPK reactivation facilitates acquired resistance in FGFR1-amplified lung cancer and underlies a rationale for upfront FGFR-MEK blockade.
P2860
Q28079309-31DF7086-1A09-4A17-A9CC-83A331DC2D37Q30249143-681DFA36-D6C7-4BFC-A2E8-0BD0E51DBE9DQ33660573-CC3CFFB5-7AC1-4761-9F34-1970EBFA8F9DQ34097937-28DEA927-AEDE-48DE-9CAF-6E36D7201B47Q34448168-731DD60B-A3D2-4184-8E0A-AAE6D8B81338Q34525925-72FAA2F5-33EB-4E28-96AA-5BF9D7A298F9Q35273337-FED6C65E-234B-4C00-B5A4-018DD97C86D7Q35527068-E3AD7196-88B8-4559-BA65-5E272BEB3BB5Q37053820-C6CCB367-5AE4-4933-8DA4-03D9F580D2C0Q37622191-C1FD0F97-C6AC-4518-8BF8-E39B80C73F42Q37682595-3C1ADBC7-880E-44B0-8B65-0E93E3F9370BQ37716485-74C491BB-19F1-45B8-A307-961051F7A3F5Q38222834-FD8C89F0-2497-4432-9FBC-966C56A476B2Q38285703-EDDB6BCF-5FDC-4F87-9240-E848E29E25ACQ38590471-3C85CD0F-2C9A-43F8-88FD-3833F68CB826Q38714068-13A754E5-CAB4-4402-8A2C-1CDDE956AD09Q38734451-8EB1AF8F-1F15-411D-B8E5-DBADED754796Q38753358-9F8BEC1F-0A96-4169-86A9-DA6C45434F26Q38939465-C360AC99-2074-464D-BD62-F3801A9C7D72Q38966912-5AE49059-07F6-40E3-AD79-8C873B33FDEEQ38987150-6E3E20DA-0C93-4886-8861-09E065B138F4Q39010445-75F40396-9EBF-481F-B6F8-842B6DA6B806Q39183442-1BCB882A-8DFD-47E0-9B13-C2E98362EF73Q41567166-88F37DFF-ECD1-4B56-B451-0B8626EFB9D8Q47406496-FB36F3C1-DE01-4988-BAE0-DA6645F275FAQ47715159-A348202D-9700-4C75-B12B-42C6DE358A48Q49791794-2FAF6B13-50AE-4434-94DB-203ED89892B9Q52589214-5C3FB6C0-46AA-4E00-9CB9-8FC1A8FA04EC
P2860
Parallel RNA interference screens identify EGFR activation as an escape mechanism in FGFR3-mutant cancer.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Parallel RNA interference scre ...... hanism in FGFR3-mutant cancer.
@en
Parallel RNA interference scre ...... hanism in FGFR3-mutant cancer.
@en-gb
Parallel RNA interference scre ...... hanism in FGFR3-mutant cancer.
@nl
type
label
Parallel RNA interference scre ...... hanism in FGFR3-mutant cancer.
@en
Parallel RNA interference scre ...... hanism in FGFR3-mutant cancer.
@en-gb
Parallel RNA interference scre ...... hanism in FGFR3-mutant cancer.
@nl
prefLabel
Parallel RNA interference scre ...... hanism in FGFR3-mutant cancer.
@en
Parallel RNA interference scre ...... hanism in FGFR3-mutant cancer.
@en-gb
Parallel RNA interference scre ...... hanism in FGFR3-mutant cancer.
@nl
P2093
P2860
P50
P1433
P1476
Parallel RNA interference scre ...... hanism in FGFR3-mutant cancer.
@en
P2093
Alex Pearson
Maria Teresa Herrera-Abreu
Nicholas C Turner
Steve D Shnyder
P2860
P304
P356
10.1158/2159-8290.CD-12-0569
P5530
P577
2013-06-06T00:00:00Z
P6179
1013193870